Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) EBT Margin (2017 - 2025)

Sutro Biopharma's EBT Margin history spans 9 years, with the latest figure at 507.54% for Q3 2025.

  • For Q3 2025, EBT Margin rose 6508.0% year-over-year to 507.54%; the TTM value through Sep 2025 reached 189.89%, down 11924.0%, while the annual FY2024 figure was 362.81%, 30518.0% down from the prior year.
  • EBT Margin for Q3 2025 was 507.54% at Sutro Biopharma, down from 15.27% in the prior quarter.
  • Across five years, EBT Margin topped out at 41.22% in Q4 2023 and bottomed at 1224.79% in Q1 2025.
  • The 5-year median for EBT Margin is 368.55% (2023), against an average of 350.78%.
  • The largest annual shift saw EBT Margin soared 44198bps in 2023 before it plummeted -77727bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 357.85% in 2021, then decreased by -12bps to 400.76% in 2022, then soared by 110bps to 41.22% in 2023, then plummeted by -1248bps to 473.28% in 2024, then decreased by -7bps to 507.54% in 2025.
  • Per Business Quant, the three most recent readings for STRO's EBT Margin are 507.54% (Q3 2025), 15.27% (Q2 2025), and 1224.79% (Q1 2025).